Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$164.42 USD
-1.26 (-0.76%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $171.82 +7.40 (4.50%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KRYS 164.42 -1.26(-0.76%)
Will KRYS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for KRYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRYS
Replimune (REPL) Gains on Positive Data From Melanoma Study
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
KRYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
Other News for KRYS
KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Krystal Biotech, Virtu, StepStone, Cactus Inc., Tidewater to join S&P 600
Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference
TD Cowen Sticks to Its Buy Rating for Krystal Biotech (KRYS)
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Krystal Biotech (KRYS) and Veeva Systems (VEEV)